Chemotherapy targeted to cancers through tumoral hormone receptors

Trends in Endocrinology and Metabolism

Volumn 15, Issue 7, 2004, Pages 300-310

  Schally, Andrew V ^a   Nagy, Attila ^a  

^a Vet Aff Med Ctr Dept Med T   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 PYRROLINODOXORUBICIN; AN 215; ANGIOTENSIN; ANTINEOPLASTIC AGENT; BETA INTERMEDIN; BEVACIZUMAB; BOMBESIN; BRADYKININ; CETUXIMAB; CHLORAMBUCIL; CYTOTOXIC AGENT; DAUNORUBICIN; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2,7 DISULFIDE; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2,7 DISULFIDE 2 PYRROLINODOXORUBICIN; DOXORUBICIN; ESTRAMUSTINE; GASTRIN RELEASING PEPTIDE; GEFITINIB; GONADORELIN; GONADORELIN RECEPTOR; GONADORELIN[6 DEXTRO LYSINE] 2 PYRROLINODOXORUBICIN; GONADORELIN[6 DEXTRO LYSINE] DOXORUBICIN; HORMONE RECEPTOR; IMMUNOTOXIN; INDIUM 111; MELPHALAN; OCTREOTIDE; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; RC 3095; SOMATOSTATIN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VAPREOTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE DERIVATIVE; YTTRIUM 90;

BINDING AFFINITY; BRAIN TUMOR; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CARCINOID; COLON CANCER; COLORECTAL CANCER; COLORECTAL CARCINOMA; DIGESTIVE SYSTEM CANCER; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; ENDOMETRIUM CANCER; GASTRINOMA; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; INSULINOMA; INTESTINE TUMOR; KIDNEY CANCER; KIDNEY CARCINOMA; LIVER CARCINOMA; LUNG CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; MELANOMA; METASTASIS; NEUROENDOCRINE TUMOR; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; STOMACH CANCER; THYROID MEDULLARY CARCINOMA; VIPOMA;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BOMBESIN; DRUG DELIVERY SYSTEMS; GASTRIN-RELEASING PEPTIDE; GONADOTROPIN-RELEASING HORMONE; HUMANS; NEOPLASMS; RECEPTORS, CELL SURFACE; SOMATOSTATIN;

EID: 4444274816     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2004.07.002     Document Type: Review

References (76)

1. K.W. Kohn Beyond DNA cross-linking: history and prospects of DNA-targeted cancer treatment-fifteenth Bruce F. Cain Memorial Award Lecture Cancer Res. 56 1996 5533 5546
2. Holland, J.F. et al. (2003) Principles of medical oncology. In Cancer Medicine (Kufe, D.W. et al., eds), pp. 637-644, BC Decker
3. th edn 2003 BC Decker
4. P. Colombo Toxicological testing of cytotoxic drugs Int. J. Oncol. 19 2001 1021 1028
5. Moscow J. et al. (2003) Drug resistance and its clinical circumvention. In Cancer Medicine (Kufe, D.W. et al., eds), pp. 711-726, BC Decker
6. Markman, M. (2003) Regional Chemotherapy. In Cancer Medicine (Kufe, D.W. et al., eds), pp. 707-710, BC Decker
7. Ehrlich, P. (1956) The relationship existing between chemical constitution, distribution and pharmacological action. In The Collected Papers of Paul Ehrlich (Vol 1) (Himmelweite, F. et al., eds), pp. 596-618, Pergamon
8. A.V. Schally, and A. Nagy Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors Eur. J. Endocrinol. 141 1999 1 14
9. D. FitzGerald, and I. Pastan Targeted toxin therapy for the treatment of cancer J. Natl. Cancer Inst. 81 1989 1455 1463
10. R.J. Kreitman, and I. Pastan Accumulation of a recombinant immunotoxin in a tumor in vivo: fewer than 1000 molecules per cell are sufficient for complete responses Cancer Res. 58 1998 968 975
11. J. Mendelsohn, and J. Baselga Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer J. Clin. Oncol. 21 2003 2787 2799
12. D.J. Slamon Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N. Engl. J. Med. 344 2001 783 792
13. H. Hurwitz Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC (ASCO) American Society of Clinical Oncology Meeting 2003 Abstract No. 3646
14. O.H. Aina Therapeutic cancer targeting peptides Biopolymers 66 2002 184 199
15. A.V. Schally Hypothalamic hormones and cancer Front. Neuroendocrinol. 22 2001 248 291
16. A.V. Schally, and A. Nagy New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin Life Sci. 72 2003 2305 2320
17. A. Nagy, and A.V. Schally Cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH); a new approach to targeted chemotherapy Drugs Future 27 2002 359 370
18. A. Nagy, and A.V. Schally Targeted cytotoxic somatostatin analogs: a modern approach to the therapy of various cancers Drugs Future 26 2001 261 270
19. Schally, A.V. and Comaru-Schally, A.M. (2003) Hypothalamic and other peptide hormones. In Cancer Medicine (Kufe, D.W. et al., eds), pp. 911-926, BC Decker
20. A.V. Schally The actions of LH-RH agonists, antagonists, and cytotoxic analogs on the LH-RH receptors on the pituitary and tumors P. Devroey Infertility and Reproductive Medicine Clinics of North America: GnRH Analogs 2001 Saunders 17 44
21. S.W.J. Lamberts Somatostatin analogs in the diagnosis and treatment of cancer Trends Endocrinol. Metab. 13 2002 451 457
22. J.C. Reubi Peptide receptors as molecular targets for cancer diagnosis and therapy Endocr. Rev. 24 2003 389 427
23. S.S. Stojilkovic, and K.J. Catt Expression and signal transduction pathways of gonadotropin releasing hormone receptors Rec. Prog. Horm. Res. 50 1995 161 205
24. G. Halmos High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers J. Urol. 163 2000 623 629
25. 6]-luteinizing hormone-releasing hormone and epidermal growth factor in human ovarian cancer Int. J. Oncol. 12 1998 489 498
26. S. Westphalen Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines Int. J. Oncol. 17 2000 1063 1069
27. R.M. Moretti Locally expressed LHRH receptors mediate the oncostatic and antimetastatic activity of LHRH agonists on melanoma cells J. Clin. Endocrinol. Metab. 87 2002 3791 3797
28. A. Nagy Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent Proc. Natl. Acad. Sci. U. S. A. 93 1996 7269 7273
29. K. Szepeshazi Effective treatment of advanced estrogen-independent MXT mouse mammary cancers with targeted cytotoxic LH-RH analogs Breast Cancer Res. Treat. 56 1999 267 276
30. A.M. Bajo Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers Clin. Cancer Res. 9 2003 3742 3748
31. Z. Kahan Complete regression of MX- 1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207 Cancer 85 1999 2608 2615
32. Z. Kahan Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice Breast Cancer Res. Treat. 59 2000 255 262
33. I. Chatzistamou Effective treatment of metastatic MDA-MD-435 human estrogen independent breast carcinomas with a targeted cytotoxic analog of luteinizing hormone-releasing hormone, AN-207 Clin. Cancer Res. 6 2000 4158 4165
34. C. Gründker Antitumor effects of cytotoxic LHRH analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice Am. J. Obstet. Gynecol. 187 2002 528 537
35. M. Miyazaki Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone J. Natl. Cancer Inst. 89 1997 1803 1809
36. M. Miyazaki Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice Am. J. Obstet. Gynecol. 180 1999 1095 1103
37. J.M. Arencibia Effective treatment of experimental ES-2 human ovarian cancers with cytotoxic analog of luteinizing hormone-releasing hormone AN-207 Anticancer Drugs 13 2002 949 956
38. M. Koppan Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice Prostate 38 1999 151 158
39. A. Plonowski Inhibition of in vivo proliferation of MDA-PCa-2b human prostate cancer by a targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 Cancer Lett. 176 2002 57 63
40. M. Letsch Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analog AN-152 in androgen sensitive and insensitive prostate cancers Clin. Cancer Res. 9 2003 4505 4513
41. L.J. Krebs Regulation of targeted chemotherapy with cytotoxic LH-RH analog by epidermal growth factor Cancer Res. 60 2000 4194 4199
42. Y.C. Patel Somatostatin and its receptor family Front. Neuroendocrinol. 20 1999 157 198
43. A. Nagy Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative 2-pyrrolinodoxonubicin Proc. Natl. Acad. Sci. U. S. A. 95 1998 1794 1799
44. Z. Kahan Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238 Int. J. Cancer 82 1999 592 598
45. G. Halmos Human ovarian cancers express somatostatin receptors J. Clin. Endocrinol. Metab. 85 2000 3509 3512
46. A. Plonowski Inhibition of the UCI-107 human ovarian carcinoma cell line by a targeted cytotoxic analog of somatostatin, AN-238 Cancer 92 2001 1168 1176
47. J.C. Reubi, and L. Kvols Somatostatin receptors in human renal cell carcinomas Cancer Res. 52 1992 6074 6078
48. A. Plonowski Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analog of somatostatin AN-238 Cancer Res. 60 2000 2996 3001
49. G. Halmos High expression of somatostatin receptors and ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers J. Clin. Endocrinol. Metab. 85 2000 2564 2571
50. A. Plonowski Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238 Cancer Res. 59 1999 1947 1953
51. M. Letsch Effective treatment of experimental models of androgen-sensitive and androgen-independent prostate cancer metastatic to the bone with targeted cytotoxic somatostatin analog AN-238 J. Urol. 171 2004 911 915
52. K.J. O'Byrne Somatostatin, its receptors and analogs, in lung cancer Chemotherapy 47 Suppl 2 2001 78 108
53. H. Kiaris A targeted cytotoxic somatostatin (SST) analogue AN-238 inhibits the growth of H-69 small cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice Eur. J. Cancer 37 2001 620 628
54. H. Kiaris Regression of U-87MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analog AN-238 Clin. Cancer Res. 6 2000 709 717
55. L. Buscail Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer Cancer Res. 56 1996 1823 1827
56. K. Szepeshazi Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancer Clin. Cancer Res. 7 2001 2854 2861
57. K. Szepeshazi Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status Cancer Res. 62 2002 781 788
58. K. Szepeshazi Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas Cancer 98 2003 1401 1410
59. A. Nagy Design, synthesis and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative 2-pyrrolinodoxorubicin Proc. Natl. Acad. Sci. U. S. A. 94 1997 652 656
60. B. Sun The presence of receptors for bombesin/GRP and mRNA for three receptor subtypes in human ovarian epithelial cancers Regul. Pept. 90 2000 77 84
61. B. Sun The presence of receptors for bombesin/gastrin-releasing peptide and mRNA for 3 receptor subtypes in human prostate cancers Prostate 42 2000 295 303
62. A. Plonowski In vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue AN-215 Int. J. Cancer 88 2000 652 657
63. A. Pansky Gastrin releasing peptide-preferring bombesin receptors mediate growth of human renal cell carcinoma J. Am. Soc. Nephrol. 11 2000 1409 1418
64. F. Cuttitta Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer Nature 316 1985 823 826
65. H. Kiaris Targeted Cytotoxic analog of bombesin/gastrin-releasing peptide inhibits the growth of H-69 human small-cell lung carcinoma in nude mice Br. J. Cancer 81 1999 966 971
66. H. Kiaris Targeting of cytotoxic bombesin analog AN-215 to H-69 small cell lung carcinomas as demonstrated by semi-quantitative microsatellite analysis in vitro Tumor Targeting 4 2000 266 270
67. T.W. Moody Human glioblastoma cell lines have neuropeptide receptors for bombesin/gastrin-releasing peptide J. Mol. Neurosci. 1 1989 235 242
68. Z. Szereday Effective treatment of experimental U-87MG human glioblastoma in nude mice with a targeted cytotoxic bombesin analogue. AN-215 Br. J. Cancer 86 2002 1322 1327
69. A. Safavy Paclitaxel derivatives for targeted therapy of cancer: toward the development of smart taxanes J. Med. Chem. 42 1999 4919 4924
70. 3 Cancer Res. 63 2003 4082 4088
71. C. Leuschner Human prostate cancer cells and xenografts are targeted and destroyed through luteinizing hormone releasing hormone receptors Prostate 56 2003 239 249
72. S.R. Denmeade Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen Cancer Res. 58 1998 2537 2540
73. S.R. Denmeade Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer J. Natl. Cancer Inst. 95 2003 990 1000
74. D. DeFeo-Jones A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo Nat. Med. 6 2000 1248 1252
75. P.S. Huang, and A. Oliff Drug-targeting strategies in cancer therapy Curr. Opin. Genet. Dev. 11 2001 104 110
76. G.M. Dubowchik, and M.A. Walker Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs Pharmacol. Ther. 83 1999 67 123